New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:37 EDTCFN, NUAN, TCK, IRG, PLD, THOR, PNG, IT, ITW, CMI, TEVA, ANR, OSK, CYS, SKUL, DE, BG, RVBDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Alpha Natural (ANR) downgraded to Fair Value from Buy at CRT Capital... Riverbed (RVBD) downgraded to Market Perform from Outperform at FBR Capital... Skullcandy (SKUL) downgraded to Neutral from Buy at Roth Capital... Teva (TEVA) downgraded to Hold from Buy at Canaccord... Bunge (BG) downgraded to Hold from Strong Buy at Feltl... CYS Investments (CYS) downgraded to Neutral from Buy at Compass Point... Deere (DE) downgraded to Buy from Strong Buy at ISI Group... Cummins (CMI) downgraded to Buy from Strong Buy at ISI Group.. Oshkosh (OSK) downgraded to Buy from Strong Buy at ISI Group... Illinois Tool Works (ITW) downgraded to Buy from Strong Buy at ISI Group... Gartner (IT) downgraded to Neutral from Overweight at Piper Jaffray... ProLogis (PLD) downgraded to Hold from Buy at Stifel Nicolaus... Nuance (NUAN) downgraded to Hold from Buy at Stifel Nicolaus... CYS Investments (CYS) downgraded to Hold from Buy at Stifel Nicolaus... PAA Natural Gas Storage (PNG) downgraded to Market Perform from Outperform at Raymond James... Ignite Restaurant (IRG) downgraded to Outperform from Strong Buy at Raymond James... CareFusion (CFN) downgraded to Outperform from Buy at CLSA... Riverbed (RVBD) downgraded to Neutral from Buy at Lazard Capital... Thoratec (THOR) downgraded to Market Perform from Outperform at Northland Securities... Teck Resources (TCK) downgraded to Neutral from Overweight at JPMorgan.
News For ANR;RVBD;SKUL;TEVA;BG;CYS;CMI;DE;OSK;ITW;IT;PLD;NUAN;PNG;IRG;CFN;THOR;TCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 30, 2015
05:55 EDTTEVATeva may be close to large acquisition, Bloomberg reports
Analysts believe Teva may be close to making a large acquisition that could be announced by September, Bloomberg reports. Teva CEO Erez Vigodman said last month hat the company is shifting to an "inorganic growth" strategy, and CRT Capital analyst Timothy Chaing says that "The closer we get to September, the closer they’re going to get to to the finish line on completing a deal or at least announcing a deal." Reference Link
March 27, 2015
10:03 EDTBGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:45 EDTTEVAFDA to hold a public meeting
Subscribe for More Information
07:25 EDTTEVATeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
06:32 EDTBGBunge upgraded to Buy from Neutral at Goldman
Subscribe for More Information
March 26, 2015
08:45 EDTITWIllinois Tool Works management to meet with FBR Capital
Meetings to be held in Los Angeles March 31-April 1 hosted by FBR Capital.
07:30 EDTTEVADeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
07:23 EDTCMIUBS to hold a field trip
Field Trip: 2015 Mid-America Trucking Show is being held in Louisville, KY on March 26.
March 25, 2015
13:13 EDTITWGraco receives FTC approval to divest certain assets to Carlisle
Subscribe for More Information
11:52 EDTSKULSkullcandy management to meet with Jefferies
Subscribe for More Information
11:08 EDTCMICummins management to meet with Jefferies
Subscribe for More Information
March 24, 2015
10:01 EDTCMIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:45 EDTTEVAFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
07:02 EDTCMICummins upgraded at RW Baird
Baird upgraded Cummins to Outperform from Neutral and raised its price target to $166 from $155. The firm said expectations have been reset and the company is poised to deliver steady earnings growth and shareholder returns. Baird believes the North American truck cycle can last longer and at higher levels than consensus expectations and thinks Cummins' stable cash flow will likely continue to enhance shareholder value.
06:22 EDTTEVATeva appointment shows transformative M&A not off table, says Citigroup
Subscribe for More Information
06:09 EDTCMICummins upgraded to Outperform from Neutral at RW Baird
March 23, 2015
16:01 EDTTEVAOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
12:10 EDTTEVATeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
08:50 EDTTEVATeva reports TEV-48125 met endpoints in phase 2b study
Subscribe for More Information
07:11 EDTCFNAlere appoints James Hinrichs to EVP and CFO effective April 6
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use